Most of the Ii-Key–related patents are already e
Post# of 36570
(Total Views: 377)
Posted On: 08/18/2025 12:20:11 AM
Most of the Ii-Key–related patents are already expired or nearing expiration. The most valuable one, US 9,289,487 B2 – “Ii-Key/antigenic epitope hybrid peptide vaccines”, officially expired on May 19, 2023, which effectively means that other companies are now free to use this technology.
The AE37 unfinished clinical trial with Merck was conducted only in combination with Keytruda, and Generex never had the opportunity to demonstrate that AE37 alone was effective. This limitation likely contributed to the bankruptcy court’s low valuation of Generex—only $150,000 —when Youfeng acquired 64% of the equity.
That also means the remaining 36% belonged to other shareholders, and as of March 2023, this minority stake was worth only about $85,000 in total.
36% value = $150,000 × (36/64)
36/64 = 0.5625
$150,000 × 0.5625 = $84,375
So the minority 36% would be $84,375
For completeness: that implies a total equity value of $150,000 / 0.64 = $234,375.
The AE37 unfinished clinical trial with Merck was conducted only in combination with Keytruda, and Generex never had the opportunity to demonstrate that AE37 alone was effective. This limitation likely contributed to the bankruptcy court’s low valuation of Generex—only $150,000 —when Youfeng acquired 64% of the equity.
That also means the remaining 36% belonged to other shareholders, and as of March 2023, this minority stake was worth only about $85,000 in total.
36% value = $150,000 × (36/64)
36/64 = 0.5625
$150,000 × 0.5625 = $84,375
So the minority 36% would be $84,375
For completeness: that implies a total equity value of $150,000 / 0.64 = $234,375.
(0)
(0)